Kısa Yanıt
Thyroid eye disease (Graves orbitopathy) is an autoimmune condition that affects the orbital tissues and eyelids. The most common eyelid manifestations are upper and lower lid retraction, causing a staring appearance and corneal exposure. Management involves treating the underlying thyroid condition, protecting the ocular surface during the active phase, and rehabilitative surgery once the disease stabilizes.
What Is Thyroid Eye Disease?
Thyroid eye disease (TED), also known as Graves orbitopathy, is an autoimmune inflammatory disorder that primarily affects the extraocular muscles and orbital fat. Autoantibodies targeting the TSH receptor in orbital fibroblasts trigger inflammation, edema, and eventual fibrosis of the orbital tissues. While most commonly associated with Graves hyperthyroidism, TED can also occur with Hashimoto thyroiditis or euthyroid states.
Eyelid Manifestations
Upper eyelid retraction
The single most common sign of TED. The upper lid sits higher than normal, exposing the sclera above the cornea (superior scleral show). It results from sympathetic overstimulation of Muller muscle, levator fibrosis, and the mechanical effect of proptosis.
Lower eyelid retraction
The lower lid drops, exposing sclera below the iris (inferior scleral show). This is caused by lower lid retractor fibrosis and gravitational effects of proptosis.
Lid lag
On downgaze, the upper lid fails to follow the globe smoothly, remaining higher than expected. This is an early clinical sign of TED.
Periorbital edema
Soft tissue swelling around the eyes is common during the active inflammatory phase, contributing to a puffy appearance.
Corneal Exposure Risk
Lid retraction combined with proptosis (forward displacement of the globe) increases the area of exposed cornea. Incomplete lid closure during sleep (nocturnal lagophthalmos) further exacerbates drying. Without adequate lubrication and surface protection, exposure keratopathy -- ranging from punctate erosions to corneal ulceration -- can develop.
Disease Phases
Active (inflammatory) phase
Characterized by periorbital swelling, redness, discomfort, and progressive changes. This phase typically lasts 6 to 24 months. Medical management aims to suppress inflammation during this period.
Stable (fibrotic) phase
Inflammation subsides and the tissue changes become static. Residual findings such as lid retraction, proptosis, and strabismus persist. Rehabilitative surgery is planned during this phase.
Medical Management
- Thyroid control: Achieving and maintaining euthyroid status is the foundation of management.
- Smoking cessation: Imperative. Smoking is the strongest modifiable risk factor for disease severity and treatment response.
- Ocular surface protection: Artificial tears, lubricating gels, and nighttime taping or moisture chambers to prevent corneal desiccation.
- Systemic immunosuppression: Intravenous or oral corticosteroids, mycophenolate, or targeted biologic therapies (e.g., teprotumumab) in moderate-to-severe active disease.
- Selenium supplementation: May have a mild benefit in recent-onset, mild TED.
Surgical Management of Eyelid Changes
Surgery follows a specific sequence once the disease is stable: orbital decompression first (if needed), then strabismus surgery, and finally eyelid surgery. This order ensures that each procedure builds on a stable foundation.
Lid retraction repair
Recession (lengthening) of the retracted lid retractors allows the lid to return to a more normal position. For the upper lid, Muller muscle and levator recession are performed. For the lower lid, retractor recession with or without a spacer graft is used.
Lateral tarsorrhaphy
A partial fusion of the outer lid margins narrows the palpebral fissure and can be performed urgently to protect the cornea during the active phase when other measures are insufficient.
Recovery After Lid Retraction Repair
First 48 hours
Lid swelling and mild bruising. Lubricating drops and ointment are used frequently. The lid position may appear over-corrected initially due to edema.
Weeks 1-2
Swelling subsides. Sutures are removed if applicable. Lid height begins to stabilize. Lubrication remains important.
Weeks 3-6
Lid position approaches the final result. Residual tightness and mild asymmetry continue to improve. Follow-up with the surgeon.
Months 2-3
Final lid position is assessed. Fine adjustments, if needed, are planned once healing is complete.
Risks
- Under- or over-correction of lid position
- Lid contour irregularity
- Recurrence of retraction if disease reactivates
- Dry eye or corneal exposure in the early postoperative period
- Need for revision surgery
Ne Zaman Acil Doktora Başvurmalı?
- •Sudden vision loss or color desaturation (possible compressive optic neuropathy -- emergency)
- •Rapidly increasing proptosis with pain and restricted eye movement
- •Corneal ulceration: pain, redness, and white spot on the cornea
- •New or worsening double vision
- •Inability to close the eyelids despite lubrication measures
Compressive optic neuropathy is a sight-threatening emergency. Seek immediate evaluation if vision changes occur.
Clinical Note
Managing eyelid changes in thyroid eye disease requires patience, staging, and close collaboration between the endocrinologist and the oculoplastic surgeon. Operating during the active inflammatory phase risks unpredictable results because the tissues are still changing. I counsel patients that the rehabilitative process follows a defined sequence -- decompression, strabismus correction, then lid surgery -- and that rushing this sequence compromises outcomes. Proper timing and careful graded lid retraction repair can restore both comfort and a natural appearance.
Frequently Asked Questions
Thyroid Eyelid Disorder Consultation
If you have been diagnosed with thyroid eye disease or notice eyelid retraction and a staring appearance, schedule an oculoplastic evaluation.
Memorial Bahçelievler Hastanesi, İstanbul
References & Sources
- American Academy of Ophthalmology (AAO). Preferred Practice Patterns — Oculoplastic Surgery.
- European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS). Clinical Guidelines.
- Nerad JA. Smith and Nesi's Ophthalmic Plastic and Reconstructive Surgery. 4th ed. Springer; 2021.
- PubMed — U.S. National Library of Medicine. Oculoplastic surgery literature.
This page is for general informational purposes only and does not replace medical examination, diagnosis, or treatment. Each patient should be evaluated individually. Treatment decisions can only be made after an in-person consultation.
Results of any surgical or interventional procedure may vary from person to person. The information on this site does not guarantee any specific treatment outcome.
Medical review: Op. Dr. Burak Akbay — Göz Hastalıkları Uzmanı | FEBO
Published:
Last updated: